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Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of
variables have been explored for understanding patients’ experiences and motivations for
medication-taking. However, oncologists’ views on adherence are poorly understood. The
aim of this study was to explore oncologists’ perspectives on adherence/non-adherence and
their strategies to ensure patients continue with treatments to inform the development of
potential modiﬁable interventions.
Methods: A qualitative study using in-depth, semi-structured interviews with 16 oncologists
was conducted in Argentina. A stratiﬁed purposive sampling was used to recruit female and
male participants from 3 health subsystems (private, social security, and public). Data were
analyzed using the Framework approach.
Results: Oncologists believed patients’ adherence was overall high and associated it with good
tolerance of AET in comparison to chemotherapy, information provided, and patients feeling
reassured (fear of recurrence). Non-adherence was not perceived as a major source of concern,
and it was related to rare cases of severe side effects, young age, refusing treatment, losing the
insurance plan, lack of education, and social circumstances. Patients’ complaints of bothersome
side effects were not identiﬁed as a main reason to discontinuation. Public and private sector
patients, however, were perceived as having different attitudes toward side effects. Management
strategies included medicine change, referral to support services, and a supportive relationship
with the oncologist.
Conclusion: Oncologists’ perspectives on adherence/non-adherence to AET show similarities
and signiﬁcant differences with those in the literature based on patient-reported factors. Overall
adherence was considered high, but the likelihood of unintentional non-adherence seems impor-
tant in public sector patients. Information to patients should provide clear explanations on both
severe and unpleasant side effects. Interventions to improve communication skills in oncologists
and specialists responsible for survivorship care should be considered to strengthen patients’ self-
efﬁcacy and effective medication-taking. Reliable data on adherence are needed.
Keywords: female cancer, hormonal therapy, medication-taking, professional perspectives,
health system provider, follow-up care
Introduction
Adherence to adjuvant endocrine therapy (AET) in clinical practice is considered as
suboptimal in developed countries, with a systematic review study indicating a
continued decline between the ﬁrst and ﬁfth year of treatment,1 and a meta-regression
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analysis estimating only a 53% of the adherers to 5 years of
treatment.2 In addition, some studies differentiate between
adherence and persistence, the former indicating “a mea-
sure of how well the patient takes the medication compared
with the instructions given by the clinician, which is daily
for endocrine therapy” (p. 1516),3 and the latter as comple-
tion of treatment over a 5-year course. The study by
Makubate et al3 ﬁrst demonstrated that only patients with
high annual adherence (taking no less than 80% of the
medication given) had better survival rates than those who
took medication for 3 years or less.
According to WHO, developing countries are consid-
ered to have a lower percentage of medication adherence in
chronic diseases in comparison to the 50% average esti-
mated for developed countries.4 In South America, only a
handful of small sample studies have analyzed adherence to
hormonal therapy for breast cancer (BC).5–8 A recent quan-
titative study in Rio de Janeiro (Brazil), based on a large
sample, reported a high rate (69%) of women being non-
persistent with 5-year treatment, measured as interrupting
or abandoning treatment for 60+days.9 Argentina has the
highest age-standardized incidence (73×100.000) and the
second highest mortality rate (18×100.000) from BC in
South America,10 which makes it a relevant country to
explore in terms of adherence given its association to mor-
tality and recurrence; however, relevant data on AETadher-
ence are missing.
Non-adherence to medication in chronic conditions is
multifaceted including societal, medical, and individual fac-
tors: social and economic factors; the health care team and
system; the characteristics of the disease; disease therapies and
patient-related factors.4 Despite this range of inﬂuences, most
quantitative and qualitative studies on AET have primarily
concentrated on patients’ behaviors and beliefs while seeking
to explore reasons for continuation and discontinuation of
treatments. Recent AET literature11,12 has drawn attention to
a necessary distinction between patients’ intentional adherence
(a conscious decision of not taking medication) and uninten-
tional adherence (individual and environmental limitations
that prevent taking medication as prescribed).13 The “neces-
sity-concern” model14 has been instrumental in analyzing
medication beliefs in BC explaining that patients weigh up
perceptions about the importance they attribute to a drug in
preventing disease recurrence against concerns with bother-
some side effects. AET is a standard treatment for womenwith
estrogen-positive BC (stages I–IV) and have proven to be
effective in reducing the risk of recurrence and in extending
survival from the disease: in postmenopausal women, 5 years
of the anti-estrogen drug Tamoxifen (TAM) reduces the risk of
recurrence by about a half and mortality by about 30%, and
aromatase inhibitors (AIs) such as anastrozole and letrozole
reduce recurrence by about two-thirds and mortality rate by
around 40%, during 10 years after initiation of treatment.47,48
TAM and AIs, however, have a number of signiﬁcant adverse
effects. Common side effects to TAM are hot ﬂushes, depres-
sion, weight gain, and low libido, and less common but severe
conditions such as increased risk of venous thromboembolism
and endometrial disorders including cancer. AIs can cause
joint pain, hot ﬂushes, and an increased risk of fractures and
osteoporosis.15
Although more evidence is needed in relation to environ-
mental factors inﬂuencing non-adherence (drug costs, health
system organization, patients’ socioeconomic status),43,44
there is consistent evidence that side effects play an important
role in patients’ decision making, either to adhere and endure
treatment16 or to intentionally discontinue treatment.1,17
Patient-reported factors inﬂuencing adherence/non-adherence
include effective communication,18,19 indicating that women
value oncologists’ information exchange on how the drugs
work and, in particular, their side effects, and professionals’
active support on how to ameliorate discomfort. In addition,
patient-centered communication and higher patient’s self-efﬁ-
cacy have been shown as positive predictors of persistence
with AET.20,21 Furthermore, a recent systematic review found
that persistence with AET was related to seeing a specialist
(oncologist or mastologist) rather than a GP,9,22 suggesting
that trust and expert advice may play a positive role.
The perspectives of health care providers on AETadher-
ence and its management, however, has been little explored
worldwide,23 and if we are to consider adherence not only
as a patient problem, there is clearly a need to analyze
oncologists and health care providers’ perspectives and
roles from AET initiation to long-term follow-up care.
The latter varies across countries where primary health
care providers such as general practitioners and/or BC
nurses are the main point of contact once women are dis-
charged from hospital. In the case of Argentina, clinical
oncologists are the chief prescribers of AETand are respon-
sible for follow-up care, although other cancer specialists
(mastologists, gynecological oncologists, radiation oncolo-
gists) can also do so for early BC, thus making all these
specialists relevant to analyze in relation to patients’ adher-
ence to medication. Whether specialists consider drug side
effects signiﬁcant or not or how they facilitate discussion on
medication-taking or manage patients’ complaints and con-
cerns with AET could have an impact on adherence. In
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addition, researchers have identiﬁed the health system orga-
nization, amongst other modiﬁable social factors, as a dri-
ver for different outcomes in cancer treatments between
afﬂuent and disadvantaged groups.46,49 The fragmented
nature of Argentina’s health system, comprising the public
sector (free of charge), social security (through employ-
ment), and private health insurance, poses a challenge to
seamless access to cancer treatments46 despite the national
coverage of free of charge, protocol-approved oncological
drugs. Problems identiﬁed in relation to AET were limited
availability of hormonal lines in the public sector in com-
parison to the private sector, difﬁculties in accessing expen-
sive drugs in the social security system, and in prescribing
drugs outside the protocol in the public sector.24 Although
the most common drugs (TAM and anastrozole) seem to be
easily accessible, it is worth noting that the population
groups assisted by providers of the three-health subsystems
vary in terms of their socioeconomic status (from most
deprived to most afﬂuent groups). Therefore, the percep-
tions that oncologists may have of patients’ characteristics,
including challenges encountered and strategies to over-
come them, can shed light on modiﬁable factors in relation
to adherence, especially in health systems with multiple
providers.1
As we know more about patients’ preferences,
experiences, and behaviors toward AET adherence, and
what patients’ value in their oncologists, this study
sought to ﬁll an important gap in the literature on
adherence which is to gain an in-depth understanding
of the perspectives of oncologists themselves. Hence,
the aim of this qualitative study was to explore oncolo-
gists’ perspectives on adherence/non-adherence to AET
and the factors inﬂuencing continuation/discontinuation
of treatments, their perceptions of medication side
effects, and their management strategies in supporting
patients’ adherence and persistence.
Materials and methods
This paper reports on data from a larger study of male and
female oncologists’ roles and practices in AET in contexts
of public/private health system providers. While ﬁndings
on prescribing practices have been reported in detail
elsewhere,24 this article focuses on perspectives and man-
agement strategies related to adherence. A stratiﬁed pur-
poseful sample was used to obtain representatives of male/
female oncologists working at three different health sub-
systems, public, private, and social security, in the city of
Córdoba, Argentina.
Participants were identiﬁed and recruited through the
Website of the largest social security provider,41 and initial
contact with heads of services and a hospital director. The
main oncology institute (public), three private clinics
(social security), and three private hospitals (private health)
were purposively selected. All oncologists interviewed
were asked to further identify other potential participants
with personal contacts, to whom the researcher contacted
via telephone and email. As clinical oncologists are the
main specialists involved in administering adjuvant therapy
(chemotherapy and hormonal treatment), they constitute the
majority of the sample (13) whilst other oncology subspe-
cialties (3) were included if they regularly prescribed AET
and managed patients’ treatment. The sample size was
initially planned for around 20 participants following the
concept of ‘information power’25 given the intrinsic fea-
tures of this study: a narrow aim, the salient knowledge of
the participants, and the availability of a theoretical back-
ground indicating that health system provider and physi-
cian’s gender could explain differences in treatment
outcomes.39,49 It was considered that these features would
offer sufﬁcient focus for the interviews. Eighteen oncolo-
gists were approached and only 16 participated (1 interested
but did not provide interview dates; 1 non-respondent). For
characteristics of the sample, see Table 1.
Table 1 Participant characteristics
No. of participants
Gender
Female 7
Male 9
Profession
Clinical Oncologist 13
Gynecologic Oncologist 2
Radiation Oncologist 1
No. Years Oncology practice
0˗5 2
6˗10 3
11˗20 4
21˗30 4
More than 30 3
Health System Provider
Public, state 6
Social health insurance 5
Private health insurance 5
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All interviews were conducted in Spanish by the author,
who is a native speaker with a research background in
medical humanities and was familiar with the local health
system organization and guidelines on clinical management
of BC hormonal treatment. All interviews were digitally
recorded with participants’ written informed consent and
took place at oncologists’ consulting rooms and hospital
ofﬁces during July 2016. Interviews lasted between 37 and
101 mins and were transcribed verbatim by a research
assistant with experience in qualitative data management.
The author subsequently checked transcripts for accuracy,
anonymized data, and translated it into English. An inter-
view guide was designed using open-ended questions and
probes and consisted of questions such as, how oncologists
considered adherence to AET; what factors they thought
inﬂuenced adherence/non-adherence; what were the
patients’ complaints regarding side effects; and how they
managed patients to ensure they remained adherent to treat-
ment (see full details Appendix 1). After preliminary ana-
lysis of the data, it was considered that sufﬁcient
information power25 regarding relevant patterns of adher-
ence perceptions and management strategies was obtained
before completing the 16 interviews.
Data analysis drew on the Framework approach, fol-
lowing its ﬁve methodological steps (familiarization with
the data, identiﬁcation of a thematic framework, indexing,
charting, and mapping and interpretation of themes).42
After familiarization with the data and identiﬁcation of
common patterns across the data set (themes), YE coded
two transcripts (male and female oncologists) from each of
the three health system providers. A working analytical
framework was created after grouping codes into cate-
gories, which were both generated by a deductive
approach informed by the interview guide and through
an inductive process based on participants’ accounts. The
working analytical framework was subsequently applied
by indexing the rest of the transcripts manually, using
textual codes. For the charting process, an Excel spread-
sheet was used to develop a matrix, consisting of a case
chart for each respondent where notes and extracts of
relevant passages were included for all identiﬁed cate-
gories and codes. This allowed for further identiﬁcation
of patterns and associations (ie, similarities and differences
in relation to oncologists’ gender and health system pro-
vider) during the mapping and interpretation process. The
process was completed through the generation of themes
and sub-themes that emerged from the data and the
research questions. To ensure reliability and conﬁrmability
of data analyzed by a single researcher, the processes of
indexing and charting were conducted in two different
stages. First, indexing and charting were developed by
using the Spanish version of the transcripts. After transla-
tion into English, a second round of indexing and charting
took place fourth months after the ﬁrst one. The cross-
checking of the two versions enhanced the process of
reﬁning themes and subthemes and ensured the elimina-
tion of ambiguity of coded terms.
Results
A total of 16 individual semi-structured in-depth inter-
views were conducted with oncologists, 9 male and 7
female doctors, with specialization in clinical oncology,
radiation oncology, and gynecological oncology. The 16
oncologists interviewed worked at 3 different health
subsystems (see Table 1). The population of women
assisted by these providers, according to data from
2010, were as follows: 69% of women were insured –
by the social security (50%), private health (17%), or
state plan (2%) – whilst a 31% were uninsured, which
means they only had access to public sector cancer
services.40
The analysis identiﬁed four themes: perceptions of
adherence; perceptions of non-adherence; patients’ com-
plaints; and management strategies. Each of these have
sub-themes. Data interpretation is reported here by using
relevant verbatim quotes to illustrate.
Perceptions of adherence
The majority of participants from all health system provi-
ders reported that adherence to AET was quite high and
considered that treatments were, overall, well tolerated.
Participants’ responses were remarkably consistent. Some
of them used expressions such as “adherence is perfect”,
“no problems”, others provided estimates of 90–95% of
the adherers. In terms of long-term persistence with treat-
ment, only one oncologist estimated 40% of the patients
discontinuing AET by the 10th year. The reasons they
provided to explain a high level of adherence were varied.
Good tolerance, comparison to chemotherapy
Some of them argued that in comparison to acute treat-
ments, especially, chemotherapy, AET was well tolerated:
“Hormonal side effects are quite limited, though it is true
that there are women who suffer a lot, and also women in
a very low percentage, that discontinue treatment because
Eraso Dovepress
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of side-effects. I am not sure, but must be a 1–2% of cases.
It is unusual, very low”. (10, male, social security)
“Adherence is, in general, very good, either TAM or AIs,
nothing to do with chemotherapy! as they don’t produce
hair loss, nauseas, vomits, we may have had a patient with
nauseas, but nothing to do with chemo. AET has far fewer
adverse reactions than chemo”. (15, male, public sector)
Information provided
For some respondents, good adherence had a direct relation
to the information provided. However, oncologists strongly
varied in their deﬁnition of “information”. As the expressions
below illustrate, one participant valued communication about
risks and beneﬁts of treatment, while another positively
emphasized the transition between active, more aggressive
treatment, and chronic treatment with medication.
“Adherence is quite high. In my view, adherence is inﬂu-
enced by the idiosyncrasies of the patient who decides to
adhere to a particular treatment, and the type of informa-
tion that she receives, and the contention that she has from
the service, from doctors, administrative staff, mental
health, nursing … You need to inform the person about
her disease with the risks and beneﬁts of taking a treat-
ment and reassure her that if she has an adverse effect you
will be able to support her, that the she won’t feel help-
less”. (2, female, public sector)
“Adherence? it is perfect […] One explains treatments at
the beginning. We tell [the patient] she will undergo
surgery; chemo (if she needs it) and we explain its
adverse effects; and then radiotherapy, where she will
come every day. And after that, we tell them there is
the little pill that she will take once a day like for any
other disease (hypothyroidism or hypertension). We tell
her that she won’t feel anything or very little. So, the
truth is that patients get to the hormonal treatment with a
very good adaptation”. (6, male, private sector)
Cancer patient attitude
Some referred to cancer patient’ attitudes toward the dis-
ease, in terms of the protection and reassurance that anti-
cancer drugs offered to control the disease:
“If you tell the patient that the current trend is 10 years,
she will be happy, she will feel protected”. (01, female,
social security)
“In general, the hormonal patients hang on to medica-
tion. There is no desertion with TAM” [.] The majority
don’t want to stop treatment they want to continue for 5
more years. They hang on to the drug because they feel
they are being treated with something”. (05, male, pri-
vate sector)
Perceptions of non-adherence
When asked about what were the reasons for patients’
non-adherence, respondents provided a range of clinical
and social factors. Some of them referred to severe side
effects, whilst others expressed other non-clinical factors
such as women’s fertility concerns, losing the insurance
plan, low education (lack of understanding), and attitudes
towards the disease where patients refused any type of
cancer treatments.
Severe side effects
Oncologist felt that severe side effects such as thromboem-
bolism, fractures, hemorrhages, and changes in the endo-
metrium were a concern and a reason to discontinue
medication, although they thought these were rare cases.
They also indicated how they routinely controlled severe
effects through different tests and medications.
“With TAM, the most common is enlargement of the
endometrium, circulatory disorders, a handful with diges-
tive ones … Anastrozole, I follow-up bone issues with
densitometry. I haven’t seen that they are worst by ana-
strozole; by taking calcium they control it perfectly”. (01,
female, social security)
“You can have higher risk of fractures with aromatase
inhibitors, with TAM a 2% risk of endometrial cancer”.
(2, female, public sector)
“We haven’t seen many side effects recently. With TAM
we are mainly concerned with vascular toxicities”. (6,
male private sector)
Refusing treatment
Other participants described that some patients were non-
adherers because they refused any type of cancer
treatment.
“Some people with advanced cases they don’t want treat-
ment and they only ask for pain-control medication”. (13,
female, public sector)
“On very few occasions we have had patients that have
abandoned treatment. I had two patients only, but they
didn’t adhere to any treatment: chemo, AET, nothing!”.
(15, male, public sector)
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Fertility concerns
Pre-menopausal women who wanted to have children were
mentioned by some oncologists as presenting a challen-
ging situation that could lead to discontinuation.
Especially women in their late 30 s for whom a 5-year
course of treatment may leave them childless.
“It is difﬁcult in pre-menopausal women without chil-
dren”. (10, male social security)
“The problems with TAM are posed by women who want
to have children. And that is very complicated”. (4,
female, social security)
Low education, life circumstances
Oncologists across the different providers stated that
patients in the public sector had more difﬁculties in keep-
ing up with their treatments and often lacked understand-
ing of medication regimes. However, public sector
oncologists said that patients continued attending appoint-
ments, and therefore they did not perceive them as com-
pletely discontinuing treatment.
“In the public sector, non-adherence happens quite often.
Mainly because of lack of education. Patients don’t under-
stand the disease, the treatment. […] Many times, it has
happened to us that we give them the medication and they
return in three months and they say, ‘I took it only once, Dr.’
[…] It is challenging… You need to constantly ask them if
they have taken the medication”. (13, female, public sector)
“There are very few cases [of non-adherence] because of
disease denial or family problems that mean that they put
their disease in a second place. Patients abandon appoint-
ments for two-three months, in occasions for one-two years,
and they resume treatment later. But they are a minority,
less than 10% of patients”. (12, female, public sector)
Oncologists in the social security and private sector also
acknowledged that patients’ socioeconomic status had an
impact on their adherence to AET medication.
“Of course, there is the fact of being a private center, where
we have a different patient population from the public
sector, with a high intellectual and social level to whom
we can more easily explain and for them to understand,
because these are chronic treatments. It is not easy for a
person to remember to take a pill every day of her life,
during 5, 8 or 10 years. And I have spoken to colleagues that
work in the public sector and they said that, sometimes,
these chronic treatments are very difﬁcult, especially as the
patient has to take them alone in their home. Sometimes it is
difﬁcult due to the social circumstances, of understanding
and so on, of that patient”. (6, male, private sector)
An oncologist who primarily worked in the private sector
but simultaneously worked for a few hours in a public
hospital commented:
“In the public sector [adherence] is a bit more erratic. Yes,
it is clear that there is a difference between the public and
private sector with a gap difference of no less than 20–
30%. In the public sector, patients rely on someone to
accompany them, on someone who can collect their med-
ication, on whether they live in the city, because we
receive patients from other provinces and they need to
cover transport costs … there are a series of factors to
consider”. (5, male, private sector)
Lack of insurance coverage
In the private sector, losing the insurance plan was seen as
a reason for discontinuation, especially in times of
employment uncertainty.
“Adherence here is very good. The only problem would be
that the patient losses her private health insurance, due to a
job change, or because the husband was made redundant.
The most important issue is that the patient keeps her
private health insurance”. (5, male, private sector)
Patients’ complaints
Oncologists were asked about what were the most com-
mon complaints they received from patients in relation to
the medicines prescribed. Most respondents were familiar
with side effects affecting women’s quality of life, and
they distinguished them from other severe side effects that
they controlled through routine follow-up tests. Notably,
and unlike the large body of literature reporting on
patients’ perspectives, bothersome side effects were not
perceived as inﬂuencing non-adherence. Only one respon-
dent identiﬁed them as causing treatment discontinuation
in a small group of patients.
Physical symptoms
The most common physical complaints oncologists
referred to were hot ﬂushes, weight gain, joint pain, and
dyspareunia. There were also a range of other physical and
psychological symptoms mentioned; however, the major-
ity of respondents did not see them as a reason to discon-
tinue treatment.
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“Everything changes, they have vaginal dryness, dimin-
ished libido, obesity, they change their bodies, they
become menopausal”. (3, female, public sector)
“Inﬂammation, cellulitis in legs, varicose veins with TAM,
a small ﬂuid retention in the legs. But this is something
cosmetic, not a functional complication. But yes, they
complain a lot about this. […] Joint pain generated by
anastrozole/letrozole that patients refer to in consultations.
But nothing serious, let’s say, there are no complications
such as fractures”. (12, female, public sector)
“The most upsetting are hot ﬂushes and weight gain, these
are by far their biggest complaints. But they don’t abandon
treatment”. (5, male private sector)
Only one oncologist clearly acknowledged that a small
group of patients had to stop the medication due to side
effects affecting women’s quality of life.
“With aromatase inhibitors not so much complaints with
hot ﬂashes, but they can give other inconveniences such as
articular pain or metabolic disorders to which we need to
control. Very occasionally these are a reason for disconti-
nuation. Well, I have women that could not be treated with
TAM, and others that could not continue treatment with
AIs because of these upsetting symptoms. I insist, it is a
very low percentage, but there is a small group”. (10, male
social security)
Some oncologists directly associated patients’ complaints
with their socioeconomic status and the health system
provider they had access to:
“The public sector patient, people with a poor economic
condition, they may have a headache, a hot ﬂush and they
won’t mention it! You have to ask them and insist a bit.
[…] Only when we ask them and explain that there are
solutions for vaginal dryness, for example, only then they
will talk about it. […] A woman from another social class
or in the private sector the ﬁrst thing they’d tell you is, ‘I
won’t take this pill, I soak the bed, I have to pull the
covers off, my husband complains … ’ Therefore, a
patient from a low socio-economic position has different
priorities, and the manifestation of symptoms affect them
differently. The public sector patient very rarely will com-
plain”. (14, male public sector)
Psychological symptoms and partner relationships
Depression, anxiety, and mood swings were the most
common physiological symptoms described. Low libido
was also seen as affecting partner relationships.
“We have experienced many times that patients came and
told us ‘my mood is lower, I cry all the time, I realized
about my disease and what I went through’ […] But I
started to see more and more cases, and they all happened
when they started TAM, we have a report of 3 or 4 cases
with these crises, but when we took them out of TAM and
changed for an AIs, it is incredible the change they made
at psychological level”. (6, male private sector)
“We know our patients, we know how they start, how they
continue, how they evolve. So, if during a check-up they
start crying, something that they hadn’t done before, we
know is due to TAM”. (13, female, public sector)
“Many patients are abandoned by their partners because of
lack of sexual relationships”. (3, female, public sector)
Management strategies
Medication change
Male doctors, in particular, expressed that they dealt with
side effects by a change in medication.
“When we have complaints with joint pain, we can change
the medication from anastrozole to letrozole or otherwise
we can change to TAM. Sometimes changing the AI the
patient tolerates it well, and there is no problem”. (15,
male, public sector)
However, another oncologist in the public sector was cau-
tioned about changing medication too often as access to
drugs was rather restricted.
“The treatment guidelines always say that one has to be
energetic, to put emphasis on the management of toxicities
in order not to skip a [hormonal] line. If the patient comes
and says that the pill gives them headache, and you change
the drug, then she complains of articular pain, when you
realized, you have exhausted all resources! And here in the
public sector we have very few resources [hormonal
lines]”. (14, male, public sector)
In the private sector, male oncologists were more certain
about switching medication to deal with unpleasant
symptoms.
“In young women with dyspareunia, who tell us, ‘I have
an active sexual life, and I don’t like this’, we can change
drugs. When they change to anastrozole the truth is that
they improve. This is a minority of cases, 1 or 2 patients
that one remembers. One knows that there is another
medication for that patient, so she won’t discontinue hor-
monal treatment”. (6, male, private sector)
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Support services
In comparison to male doctors, female doctors often
described the use of support services for mental health
and menopause symptoms, including the prescription of
adjunctive medications that offered some symptom relief.
“We refer them to a center that deals with menopausal
services, within public maternities, to see which medica-
tion can be given, anxiolytics or anti-depressants for hot
ﬂushes, so it can be managed and the patient can improve.
[…] In general, it hasn’t happened to me that there was a
need to change medication for an intolerance that the
patient has expressed. The cosmetic, joint pain, we man-
age”. (12, female, public)
“I am sure this is related to TAM, but we cannot stop the
medication, we have to treat the depression, so we advise
them psychological therapies, or to take a break from work
if possible, or sometimes a change of diet alongside phy-
sical activities”. (16, female, private sector)
Supportive relationship with oncologist
Some female doctors highlighted the importance of their
relationship with patients in managing women who might
want to abandon treatment and described the support they
offered to motivate them.
“Complaints? No problems. I convince them. I have a very
good relationship with them. I am very proactive, for the
patient to be stimulated, to feel good, to be a woman […]
If they don’t want to take TAM or another drug, well I
give them a ‘holiday’, I tell them: ‘when you want it you
will come and pick it up’ (the drug) and they come back
[…] In intermediate patients [not a high risk], I give them
time to think about it”. (3, female, public sector)
Another female doctor referred to the importance of mon-
itoring emotional symptoms such as anxiety and depres-
sion, something that she also considered needed to be
informed to patients at the time of treatment initiation.
“I closely observe patients in relation to depression, I have
a lot of attention to detail with my patients. It is a reaction
to TAM, and we need to bear this in mind. And we need to
let patients know, tell them not to feel bad, that it is due to
the medication, that is part of the treatment. We often say
this at the beginning of treatment, that is something that
can happen”. (13, female, public sector)
Some oncologists in the private and social security sector
referred to other challenges they experienced such as
extending hormonal therapy to 10 years, whereby they felt
that expert trust was a relevant factor in managing
continuation.
“The main complaint at the moment is a sub-group of
patients to whom we tell they need to take the medication
for 10 years. In these cases, it is like the patient had
mentalized herself that treatment was for 5 years, and
sometimes this shocks them, and some express a bit of
irritation, but nothing that we couldn’t manage. And in
general, they end up doing what we suggest to them”. (7,
male private)
Discussion
This study explored oncologists’ perspectives on adher-
ence/non-adherence to AET and the management strate-
gies they use to ensure treatment continuation in women
with early BC. Oncologists believed patients’ adherence
was high overall and explained that it was associated with
good tolerance of AET in comparison to chemotherapy,
information provided, and patients’ feeling reassured
because of treatment. Non-adherence was not perceived
as a major source of concern, and it was related to rare
cases of severe side effects, fertility issues, refusing treat-
ment, losing the insurance plan, lack of education, and
social circumstances. Patients’ complaints over bother-
some side effects were not identiﬁed as the main reason
for discontinuation. Public and private sector patients,
however, were perceived as having different attitudes
toward side effects. Management strategies included med-
icine change, referral to support services, and a supportive
relationship with the oncologist.
Although most respondents considered adherence as
very high, none of them mentioned how this was estimated.
In the absence of a monitoring strategy, adherence to treat-
ment based on patients’ attendance to follow-up appoint-
ments and self-reported attitudes toward medication can
create a false sense of treatment adherence that cannot
account for medication-taking behavior, ie, missing drugs,
or taking breaks, as it has been reported in other studies.26
Although oncologists did not explicitly differentiate
between intentional and unintentional non-adherence, their
accounts indicate that intentional non-adherence is low, but
unintentional non-adherence is rather high, especially in
public sector patients. This ﬁnding is consistent with a
quantitative study on patients taking TAM that reported a
high proportion of unintentional non-adherence12 and adds
Eraso Dovepress
submit your manuscript | www.dovepress.com
DovePress
Patient Preference and Adherence 2019:131318
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
0.
97
.3
5.
10
3 
on
 0
9-
Se
p-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
weight to the role of social factors affecting adherence in
low-income women.
The perception of adherence as related to cancer
patient attitudes of feeling reassured and protected while
in treatment (fear of recurrence) is consistent with studies
reporting on anastrozole30 and TAM,31 where adherers
expressed an imperative and a necessity to keep them-
selves on the treatment regardless of bothersome side
effects. In addition, information on AET provided to
patients at the time of treatment initiation was acknowl-
edged as relevant only by some oncologists. Yet the con-
tent of the information given substantially varied: from
reassurance that AET was more tolerated than chemother-
apy, to an explanation of risks and beneﬁts of treatments.
Timely information about side effects has been identiﬁed
in the literature as a relevant factor associated with
adherence,32 however, and similarly to this study, a
European survey reported that women were more likely
to receive information about the beneﬁts of AET (68%)
than information about side effects (57%).33
Socioeconomic status and patients’ behavior observed
through users of the private and public health subsystems
is another factor respondents identiﬁed as affecting non-
adherence and patients’ complaints, which has been under-
explored in the literature. This was speciﬁcally linked to
two related instances: health literacy and self-efﬁcacy. On
the one hand, health literacy has been associated to unin-
tentional non-adherence when individuals “struggle to
comprehend instructions on prescribed medicines and con-
sequently may take the wrong dosage at the wrong time or
mix up medicines” (p.12).27 In this study, “lack of educa-
tion” and “understanding” of medication-taking were
expressed as a concern by oncologists assisting low-
income patients. On the other, self-efﬁcacy, here consid-
ered as the conﬁdence of patients to ask questions in
medical encounters, indicates that afﬂuent users of the
private health system were identiﬁed as more complaining
and able to express discomfort and to demand a change of
medication. Conversely, most deprived women were
described as being disempowered to express undesirable
symptoms. The later can lead to unintentional non-adher-
ence, as a previous study has associated high self-efﬁcacy
in low-income women with greater adherence.21
It is also noteworthy that oncologists’ perceptions of
non-adherence contrast with those in the literature based
on patient-reported experiences (see Table 2). Revealingly,
many respondents considered non-adherence a medical
concern with severe side effects, indicating that patients’
continuation with one drug was dependent on clinical
observations of other medical pathologies, ie, increased
risk of thromboembolism, osteoporosis, or engrossment
of the endometrium. Non-adherence in this sense was
perceived as a doctor’s responsibility for routine check-
ups rather than dependent on patients’ own experiences
with medication. This corresponds with the overall percep-
tion that intentional non-adherence was low. However, it
contrasts with the large body of research that associates
non-adherence to patients’ burdensome experiences with
drug side effects. Oncologists seemed aware and con-
cerned with the monitoring and management of severe
side effects (medical, objective and life-threatening), but
they were less so in relation to the unpleasant ones (per-
sonal, subjective, affecting quality of life). Although some
retrospective studies on AIs associate the likelihood of
unpleasant side effects to previous chemotherapy
treatment,28 it still remains difﬁcult to predict which
patients will suffer them more15 which can lead doctors
to regard them as less relevant. In this study, and despite
one doctor referring to “some women” as being seriously
affected, only rarely they viewed these symptoms as a
reason to discontinue treatment. It may also be the case
that unpleasant side effects, in comparison to the risk-
Table 2 Participants’ perceptions of intentional and unintentional non-adherence
Intentional non-adherence Unintentional non-adherence
Refusing any type of treatment Low health literacy (no understanding of: disease, treatment, or medi-
cation regime)
Severe side effects (vascular toxicities, thromboembolism, endometrial
disorders)
Distance to service (transport costs)
Fertility concerns Lack of family support/being alone
Loosing insurance coverage Having other pressing problems
Low self-efﬁcacy (inability to ask questions)
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assessed severe ones, are highly subjective, in that women
can experience them and decide to tolerate them for the
beneﬁt of cure/protection.16 Oncologists’ perceptions of
unpleasant side effects also resonate with ﬁndings from a
Dutch observational study where oncologists often made
use of “implicit persuasion” (ie, inducing patients’ choice)
during consultations about treatment options, by under-
reporting and downplaying the impact of AET in patients’
quality of life.45 If oncologists tend to minimize these side
effects during follow-up care, as it seems that is the case in
this study, then expectations of adherence could have
negative implications for both patients (if symptoms are
worse than initially thought) and professionals (overesti-
mating tolerance and adherence). Finally, it is also impor-
tant to consider the context of survivorship care whereby
the Argentinian recommendation guidelines on follow-up
appointments,29 state the clinical tests a patient should
have (annual mammography, pelvic exam, bone densito-
metry), but surprisingly, they state nothing about monitor-
ing adherence to medication or discussing with patients the
management of adverse effects.
Management strategies reported by oncologists to ensure
adherence and persistence in this study appeared to differ
according by gender. As reported previously during AET
prescribing,24 female oncologists seemed to develop more
partnership-building behaviors. The identiﬁcation of
patients’ depression and mood swings, as well as the nature
of communication exchange (partner relationships, cosmetic
concerns), reveals a more empathetic, person-centered type
of communication.38,39 From attention to detail to proactive
motivation, female oncologists expressed greater awareness
of unpleasant side effects, whilst allowing them to use dif-
ferent strategies, ie, support services, adjunctive medicines,
and medication breaks. With few exceptions, male oncolo-
gists referred to initiatives that drew more on drug effective-
ness and resorted to switching medication (to AIs or TAM or
to different brands of the same drug) in follow-up care
appointments. This approach was often mentioned in the
private health system where access to a larger number of
hormonal lines was reported as less complicated.
The ﬁndings of this study have a number of recom-
mendations for managing adherence. First, the need for
data on adherence and persistence in Argentina, collected
through a reliable measurement (prescription reﬁlls) across
the health system providers; private, public, and social
security. Lack of statistics was felt as a need by some
oncologists, and having this information will certainly
provide a better understanding of the magnitude of the
adherence/persistence problem as well as identiﬁcation of
which one is in need of effective interventions.
Information to patients should consider clear explana-
tions on both severe and unpleasant side effects so women
are prepared for and understand the symptoms that are
likely to occur and are reassured on the different types of
support available. There is evidence that indicates that
switching medication (from TAM to AIs or vice versa)
can lead to poor adherence;1,34 therefore, other effective
coping strategies should be explored.35
Interventions to improve communication skills in oncolo-
gists and specialists responsible for survivorship care such as
motivational interviewing strategies and techniques36,37 could
offer health care professionals with a better identiﬁcation of
barriers to medication-taking (intentional and unintentional)
and women with opportunity to discuss symptoms and pro-
blems, thus strengthening their self-efﬁcacy and effective
medication-taking over a long-term course of therapy.
Recommendation guidelines on follow-up appointments
should incorporate discussion on AET medication-taking,
unpleasant side effects, and coping mechanisms, so women
are encouraged to discuss emerging problems during follow-
up. In addition, interventions aiming at coordination of care,18
such as signposting women to a telephone communication
with an oncology nurse could be considered as part of the
supporting strategies between scheduled appointments.
Strengths and limitations
To our knowledge, this is the ﬁrst study to explore oncologists’
perceptions of adherence/non-adherence to AET in Argentina.
The study sample was representative of the three sector pro-
viders within the Argentinian health system and of profes-
sionals’ gender, and their accounts elicited some interesting
differences and similarities within and between services. In
terms of limitations, there is a paucity of qualitative and
quantitative studies in this ﬁeld of research in the Latin
American context, and hence contextual comparisons were
rather limited. As with all qualitative studies, a small sample
size means that results may not be generalizable. Yet, in-depth
interviews offer a distinct insight into the way adherence to
AET is perceived and managed by professionals, especially in
contexts where little research is available, allowing us to
advance the knowledge based in this area.
Conclusion
Overall, the ﬁndings of this study on oncologists’ perspec-
tives on adherence/non-adherence to AET show similarities
and signiﬁcant differences with those in the literature based
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on patient-reported factors. It is crucial that oncologists con-
sider providing information to patients on both severe and
unpleasant side effects and that they monitor adherence and
offer support strategies in follow-up appointments. Although
reliable statistics on adherence and persistence are needed,
oncologists accounts have indicated concern with uninten-
tional non-adherence.
Recommendations include motivational interviewing
strategies, engagement with an oncology nurse, and chan-
ging national recommendation guidelines to ensure the
monitoring of adherence in follow-up care.
Abbreviation list
AET, adjuvant endocrine therapy; AI, aromatase inhibi-
tors; BC, breast cancer; TAM, Tamoxifen.
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Interview question guide
1. How do you consider patient adherence to AET in
your clinic?
2. Do you have access to data on adherence?
3. What factors do you think can inﬂuence patients’
decision to adhere? (probes: information provided,
cancer fear, trust in treatment).
4. What factors do you think can inﬂuence patients’
decision to not initiate AET medication?
5. Do patients discontinue medication before completing
the 5 years? If so, can you identify their reasons?
(probes side effects, socio-economic factors u others).
6. How often do you see your patients after they are
discharged from clinic?
7. What are the main complaints regarding side effects
that you receive from your patients? (probes physical
symptoms, psychological symptoms).
8. How do you manage patients’ complaints about med-
ication? (probes change of drugs, social services, non-
medical treatment).
These questions correspond to a section of the interview
guide regarding adherence to treatments. These questions
were preceded by a set of questions about oncologists
prescribing AET by Eraso.1
Reference
1. Eraso Y. Factors inﬂuencing oncologists’ prescribing hormonal ther-
apy in women with breast cancer: a qualitative study in Córdoba,
Argentina. Int J Equity Health. 2019; 18(1):35. doi:10.1186/s12939-
019-0936-z
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